Key Decisions for Life Science Companies: Stay the Course or Exit via M&A?
By Andrew Levitch, Mark Murray, Patrick Nugent, Linda Rubinstein
This article is the fourth in a 4-part series reviewing financing solutions for the Life Science sector. Many life science companies are fortunate to reach a critical inflection point where leadership must face a decision: continue to fund growth to reach clinical milestones independently or exit via merger and acquisition….Read More
Read MorePre-Acquisition Planning for Post-Acquisition Integration
By Andrew Levitch
As all CEOs and management teams know, there are many challenges to successfully completing an acquisition. These range from identifying the right acquisition target through complex target-acquirer negotiations and ultimately to finalizing terms and closing the deal. But one of the challenges of M&A that often doesn’t get enough attention…Read More
Read MoreThe M&A Challenge of Acquiring a Private, Foreign-Owned Company
By Kenton Chow
Experienced CFOs know that merger and acquisition (M&A) deals can be complicated and demanding, from finding a strategic fit to conducting due diligence to post acquisition integration. And M&A is even more challenging when one private company acquires another private company, especially if it is a cross-border acquisition. Mergers and…Read More
Read MoreMergers and Acquisitions: Strategies for Optimizing ROI for Investors
By Bill Leetham
All privately-funded companies reach a point when, at some point, investors and founders want to receive a return on their investment. And while some startups exhibit the business models, revenue growth, market share and earnings potential to go public through an IPO, very few check all the boxes and make…Read More
Read More